Protective Role of the Portocaval Shunt in Liver Transplantation

• Published in: Transplantation proceedings Vol. 52; no. 5; pp. 1455 - 1458
• Main Authors: Tortolero, Laura, Nuño, Javier, Buenadicha, Adolfo, Gajate, Luis, Serrano, Ana, Liaño, Fernando, Peromingo, Roberto, Hervás, Pedro López
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2020
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2020.01.089

Advances in medical management and surgical technique have resulted in stepwise improvements in early post-transplant survival rates. Modifications in the surgical technique, such as the realization of the portocaval shunt (PCS), could influence survival rates. The aim of this study was to evaluate the mortality rate for 12 months after liver transplantation, analyzing the causes and risk factors related to its development and assessing the impact that PCS could have on them.
A total of 231 recipients were included in the retrospective, longitudinal, and nonrandomized study.
The overall survival of the transplant was 85.2% (197 patients). The most frequent cause of death was infection (38.2%), followed by the multiorgan failure of multiple etiology (23.5%). Most of the risk factors related to mortality correspond to variables of the postoperative period. The results of the multivariate analysis identified the main risk factors for death: the presence of surgical complications and the need for renal replacement therapy. In contrast, the performance of PCS exerted a protective effect, reducing the probability of death by 70%.
Despite the good results obtained in several studies, there is still debate regarding the benefit of its realization. In our study, PCS was a factor associated with a reduction in mortality, with a markedly lower probability of adverse events. However, we agree with other authors on the need for larger and randomized studies to adequately determine the validity of such results.
•Modifications in the surgical technique, such as the realization of the portocaval shunt, could influence survival rates.•The most frequent cause of death after liver transplantation is infection.•The use of basiliximab did not show, in our population, a relationship with the risk of death.•The performance of portocaval shunt exerted a protective effect, reducing the probability of death by 70%.